German biotech company BioNTech plans to establish regional headquarters for Southeast Asia in Singapore. It also plans to open its first production facility in Singapore to manufacture mRNA-based vaccines with support from the Singapore Economic Development Board (EDB).

According to a press release dated May 10, the new facility will produce a range of mrNA vaccines and therapeutics for infections diseases and cancer, with an estimated annual capacity of several hundred of million doses of mRNA-based vaccines depending on the specific vaccine.

BioNTech plans to open its Singapore office and initiate construction of the manufacturing facility in 2021, subject to planning approval. The company anticipates that the site could be operational as early as 2023 and will create up to 80 jobs in Singapore.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook